Literature DB >> 8698062

Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer.

F Kraeber-Bodéré1, A Mishra, P Thédrez, A Faivre-Chauvet, M Bardiès, S Imai, J Le Boterff, J F Chatal.   

Abstract

The use of samarium-153 in the context of radioimmunotherapy of cancers has been limited by the instability of antibody labelling, which produces high uptake concentrations in liver and bone. This study compares the pharmacokinetics and biodistribution of 153Sm-labelled OC125 monoclonal antibody, in whole or F(ab')2 fragment form and with diethylene triamine penta-acetic acid (DTPA) or 6-p-isothiocyanatobenzyl diethylene triamine penta-acetic acid (CITCDTPA) coupling, in nude mice grafted subcutaneously with an ovarian adenocarcinoma line (SHIN-3) expressing CA125 antigen. The specific activity of the immunoconjugates was 18.5-55.5 MBq/mg, and their immunoreactivity exceeded 65%. With 153Sm-DTPA-OC125F(ab')2, the stability study in serum indicated that 50% of the metal remained bound to the antibody. The pharmacokinetic study showed a retention half-life of 25.1 h and blood clearance of 0.72 ml/h. The biodistribution study indicated tumour uptake of 4.53%+/-0.49% of injected activity per gram (%ID/g) at 24 h and tumour-to-liver and tumour-to-bone ratios of 0.23+/-0.02 and 1.54+/-0.49 respectively at 24 h. With 153Sm-CITCDTPA-OC125F(ab')2, serum stability was greater (87% of the metal remaining bound to the antibody), retention half-life was 22.25 h and blood clearance was 2.23 ml/h. Tumour was better targeted (8.30%+/-3.56%ID/g at 24 h), and tumour-to-liver and tumour-to-bone ratios were 1.17+/-0.36 and 7.08+/-3.09 respectively at 24 h. However, renal retention remained elevated (29.76%+/-9. 41%ID/g at 24 h). With intact IgG, renal uptake decreased (1.41%+/-0. 49%ID/g at 24 h), but tumour uptake was lower than with fragments (1. 46%+/-0.58%ID/g at 24 h). Liver uptake was higher (tumour-to-liver ratio 0.10+/-0.05), and blood clearance was slower. The stability and distribution of 153Sm-CITCDTPA were more favourable than those of 153Sm-DTPA for application in radioimmunotherapy. Quantitative analysis performed using digitized images obtained by conventional autoradiography and the imaging plate system indicated that the latter system is suitable for biodistribution studies of immunoconjugates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698062     DOI: 10.1007/bf00833392

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  35 in total

1.  Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.

Authors:  J L Klein; T H Nguyen; P Laroque; K A Kopher; J R Williams; B W Wessels; L E Dillehay; J Frincke; S E Order; P K Leichner
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

2.  A centrifuged-column procedure for the measurement of ligand binding by beef heart F1.

Authors:  H S Penefsky
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Stabilities of lanthanide-protein complexes.

Authors:  K Schomäcker; D Mocker; R Münze; G J Beyer
Journal:  Int J Rad Appl Instrum A       Date:  1988

4.  Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat brain.

Authors:  J H Ryu; K Yanai; R Iwata; T Ido; T Watanabe
Journal:  Neuroreport       Date:  1994-01-31       Impact factor: 1.837

5.  Computed radiography utilizing scanning laser stimulated luminescence.

Authors:  M Sonoda; M Takano; J Miyahara; H Kato
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.

Authors:  R Stein; R Blumenthal; R M Sharkey; D M Goldenberg
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

7.  Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.

Authors:  J F Chatal; J C Saccavini; J F Gestin; P Thédrez; C Curtet; M Kremer; D Guerreau; D Nolibé; P Fumoleau; Y Guillard
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

8.  Quantitative whole-body autoradiography of radiolabeled antibody distribution in a xenografted human cancer model.

Authors:  I Fand; R M Sharkey; W P McNally; A B Brill; P Som; K Yamamoto; F J Primus; D M Goldenberg
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

9.  Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice.

Authors:  L F Massuger; O C Boerman; F H Corstens; R H Verheijen; R A Claessens; L G Poels; W J van den Broek; P Kenemans
Journal:  Anticancer Res       Date:  1991 Nov-Dec       Impact factor: 2.480

10.  Receptor autoradiography with 11C and [3H]-labelled ligands visualized by imaging plates.

Authors:  K Yanai; J H Ryu; T Watanabe; R Iwata; T Ido
Journal:  Neuroreport       Date:  1992-11       Impact factor: 1.837

View more
  4 in total

1.  Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.

Authors:  Gui-Ping Li; Hui Zhang; Cheng-Mo Zhu; Jian Zhang; Xu-Feng Jiang
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

Review 2.  In situ imaging of metals in cells and tissues.

Authors:  Reagan McRae; Pritha Bagchi; S Sumalekshmy; Christoph J Fahrni
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

3.  Targeted delivery of platinum-taxane combination therapy in ovarian cancer.

Authors:  Swapnil S Desale; Kruti S Soni; Svetlana Romanova; Samuel M Cohen; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-09-14       Impact factor: 9.776

4.  Establishment of a new representative model of human ovarian cancer in mice.

Authors:  Jianjun Zhang; Xinlian Chen; Gang Shi; Xiaoyan Xie; Hongqian Liu; Xuemei Zhang; Yi Lai; Yan Zuo; Zhong Chen; Shanling Liu; He Wang
Journal:  J Ovarian Res       Date:  2013-02-06       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.